Real-World Eylea HD Data Presented at ARVO

Initial data from nearly 40,000 patients demonstrate early visual improvements and reduced injection frequency.

By: Jim Gallagher, senior managing editor

Retinal Physician May 8, 2025

Clinical Report: Real-World Eylea HD Data Presented at ARVO

Overview

Revise to emphasize the clinical relevance of visual acuity improvements in treatment-naïve patients.

Background

The management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) often requires frequent intravitreal injections of anti-VEGF therapies. Reducing the frequency of these injections can alleviate the treatment burden on patients while maintaining visual outcomes. Real-world data can provide insights into the effectiveness and safety of newer formulations like Eylea HD in clinical practice.

Data Highlights

Verify and correct the injection intervals and visual acuity improvements to match the source data.

Key Findings

Nearly 40,000 eyes treated with Eylea HD showed early visual improvements.
Switching to Eylea HD extended injection intervals by 2-3 weeks in previously treated DME patients.
Treatment-naïve DME patients with poor baseline vision improved by 7.9 to 9.6 letters within 90 days.
Post-loading phase injection intervals averaged 63 to 69 days in treatment-naïve patients.
No new safety signals were identified in the real-world studies.

Clinical Implications

The findings support the use of Eylea HD as a viable option for reducing treatment burden in patients with nAMD and DME. Clinicians may consider longer dosing intervals for patients who demonstrate early visual improvements, potentially enhancing patient adherence to treatment.

Conclusion

Eylea HD demonstrates promising real-world effectiveness in improving visual acuity and extending injection intervals, which may significantly benefit patient management in nAMD and DME.

PentaVision

Retinal Physician